Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer and Response to Checkpoint Inhibition

被引：4
|
作者：
Zang, Peter D. [1 ]
Chawla, Neal S. [1 ]
Barragan-Carrillo, Regina [1 ]
Chehrazi-Raffle, Alex [1 ]
Tripathi, Abhishek [1 ]
Pal, Sumanta K. [1 ]
Dorff, Tanya B. [1 ]
机构：
[1] City Hope Comprehens Canc Ctr, Dept Med Oncol & Expt Therapeut, Duarte, CA USA
来源：
JAMA ONCOLOGY | 2024年 / 10卷 / 04期
关键词：
IPILIMUMAB;
D O I：
10.1001/jamaoncol.2023.6817
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
This single-center cohort study assesses the association of tumor mutational burden status in patients with metastatic castration-resistant prostate cancer and response to immune checkpoint inhibitor therapy.
引用
收藏
页码：531 / 532
页数：2
相关论文
共 50 条
  • [31] PARP inhibition in castration-resistant prostate cancer
    Nappi, Lucia
    Gleave, Martin E.
    FUTURE ONCOLOGY, 2016, 12 (05) : 577 - 580
  • [32] Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
    Ruiz de Porras, Vicenc
    Pardo, Juan Carlos
    Notario, Lucia
    Etxaniz, Olatz
    Font, Albert
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (09)
  • [33] Tumor mutational burden as a predictive biomarker for immune checkpoint inhibitor versus taxane chemotherapy benefit in metastatic castration-resistant prostate cancer: A real-world biomarker study.
    Sayegh, Nicolas
    Graf, Ryon
    Fisher, Virginia
    Weberpals, Janick
    Huang, Richard S. P.
    Lin, Douglas I.
    Gjoerup, Ole
    Raskina, Kira
    Severson, Eric Allan
    Haberberger, James
    Ross, Jeffrey S.
    Alexander, Brian Michael
    Levy, Mia Alyce
    Oxnard, Geoffrey R.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [34] Inhibition of TAMs improves the response to docetaxel in castration-resistant prostate cancer
    Guan, Wei
    Hu, Junhui
    Yang, Lu
    Tan, Ping
    Tang, Zhuang
    West, Brian L.
    Bollag, Gideon
    Xu, Hua
    Wu, Lily
    ENDOCRINE-RELATED CANCER, 2019, 26 (01) : 131 - 140
  • [35] Impact of intervening in high-risk nonmetastatic castration-resistant prostate cancer (HRnmCRPC) on metastatic castration-resistant prostate cancer (mCRPC) disease burden.
    Small, Eric Jay
    Saad, Fred
    Zheng, Ying
    Pan, Feng
    Mehra, Maneesha
    Lawson, Joe
    Hadaschik, Boris A.
    Uemura, Hiroji
    Lee, Ji Youl
    Mainwaring, Paul N.
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] The Role of Microsatellite Instability/DNA Mismatch Repair Deficiency and Tumor Mutational Burden as Biomarkers in Predicting Response to Immunotherapy in Castration-resistant Prostate Cancer
    Kluemper, Niklas
    Gruenwald, Viktor
    Hartmann, Arndt
    Hoelzel, Michael
    Eckstein, Markus
    EUROPEAN UROLOGY, 2024, 86 (05) : 388 - 390
  • [37] Tumor testing and treatment patterns in veterans with metastatic castration-resistant prostate cancer
    Hung, Anna
    Candelieri, Danielle
    Li, Yanhong
    Alba, Patrick
    Robison, Brian
    Agiri, Fatai
    Perez, Cristina
    Lee, Kyung-Min
    Maxwell, Kara N.
    Li, Weiyan
    Aggarwal, Himani
    Pridgen, Kathryn
    Reed, Shelby D.
    DuVall, Scott
    Wong, Yu-Ning
    Lynch, Julie A.
    SEMINARS IN ONCOLOGY, 2023, 50 (1-2) : 11 - 24
  • [38] Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer
    Sonpavde, Guru
    Agarwal, Neeraj
    Pond, Gregory Russell
    Nagy, Rebecca J.
    Nussenzveig, Roberto H.
    Hahn, Andrew W.
    Sartor, Oliver
    Gourdin, Theodore Stewart
    Nandagopal, Lakshminarayanan
    Ledet, Elisa M.
    Naik, Gurudatta
    Armstrong, Andrew J.
    Wang, Jue
    Bilen, Mehmet Asim
    Gupta, Shilpa
    Grivas, Petros
    Pal, Sumanta K.
    Lanman, Richard B.
    Talasaz, AmirAli
    Lilly, Michael B.
    CANCER, 2019, 125 (09) : 1459 - 1469
  • [39] The Role of Microsatellite Instability/DNA Mismatch Repair Deficiency and Tumor Mutational Burden as Biomarkers in Predicting Response to Immunotherapy in Castration-resistant Prostate Cancer
    Kluemper, Niklas
    Eckstein, Markus
    EUROPEAN UROLOGY, 2025, 87 (01) : e17 - e18
  • [40] The economic burden of metastatic castration-resistant prostate cancer: US Medicare perspective.
    Eapen, Sara
    Andrews, Ryan M.
    Gorin, Brian
    Higano, Celestia S.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345